Targeting mutant p53 stabilization for cancer therapy

Over 50% cancer bears TP53 mutation, the highly stabilized mutant p53 protein drives the tumorigenesis and progression. Mutation of p53 not only cause loss-of-function and dominant-negative effects (DNE), but also results in the abnormal stability by the regulation of the ubiquitin-proteasome system...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiajian, Liu, Wenjun, Zhang, Lanqing, Zhang, Jihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369794/
https://www.ncbi.nlm.nih.gov/pubmed/37502209
http://dx.doi.org/10.3389/fphar.2023.1215995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369794/
https://www.ncbi.nlm.nih.gov/pubmed/37502209
http://dx.doi.org/10.3389/fphar.2023.1215995

Ejemplares similares